{"id":"W2103134643","doi":"10.1200/jco.2004.06.075","title":"Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":808,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Rash; Internal medicine; Tolerability; Epidermal growth factor receptor; Mucositis; Oncology; Head and neck cancer; EGFR inhibitors; Population; Erlotinib Hydrochloride; Phases of clinical research; Gastroenterology; Cancer; Adverse effect; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002106501,0.001215019,0.001785056,0.0002262386,0.0003180378,0.000703842,0.0006477883,0.00068441,0.001613086],"category_scores_gemma":[0.000889921,0.0004642841,0.001078316,0.0002897434,0.0006074752,0.0004936269,0.0002428098,0.001684646,0.0004459275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008191516,"about_ca_system_score_gemma":0.001491287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001206787,"about_ca_topic_score_gemma":0.003443283,"domain_scores_codex":[0.9993617,0.0003651098,0.00003349616,0.00009101459,0.00006240576,0.00008627523],"domain_scores_gemma":[0.9992998,0.0001055175,0.0001915679,0.00005003209,0.00006195549,0.000291157],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7329617,0.04423915,0.05068405,0.0008212522,0.003645703,0.00045224,0.0005080007,0.003344554,0.06991801,0.0001781971,0.003809934,0.08943741],"study_design_scores_gemma":[0.5856938,0.3456258,0.05805523,0.00003539109,0.001174525,0.0005151719,0.00009046193,0.001992816,0.004776677,0.00007575379,0.001926667,0.00003767498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969577,0.001080057,0.0002800728,0.0001370089,0.00003922379,0.0007924554,0.0003652174,0.00002376112,0.0003245817],"genre_scores_gemma":[0.9955381,0.0007549225,0.0007848167,0.00026957,0.00008888458,0.0007735993,0.001081944,0.00001228187,0.0006958179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002106501,"threshold_uncertainty_score":0.01114041,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1174694466171304,"score_gpt":0.4563328035458323,"score_spread":0.3388633569287018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}